Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer

Oncology

Volumn 80, Issue 3-4, 2011, Pages 269-277

  Nikolényi, Alíz ^a   Sükösd, Farkas ^b   Kaizer, László ^b   Csörg, Erika ^b   Vörös, András ^b   Uhercsák, Gabriella ^a   Ormándi, Katalin ^b,d   Lázár, György ^c   Thurzó, László ^a   Brodowicz, Thomas ^e   Kahán, Zsuzsanna ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Department of Pathology ^*  (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d Euromedic Diagnostics Szeged Ltd   (Hungary)

^e Central European Cooperative Oncology Group   (Austria)

Author keywords

Anthracyclines; Breast cancer; Chemosensitivity; Primary neoadjuvant chemotherapy; Topoisomerase II alpha

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79959830757     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000329038     Document Type: Article

References (37)

1. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18: 1927-1934. (Pubitemid 350286227)
2. Steger GG, Greil R, Jakesz R, Lang A, Mlineritsch B, Melbinger-Zeinitzer E, Marth C, Samonigg H, Kubista E, Gnant M: Final results of ABCSG-24, a randomized phase III study comparing epiribicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer (abstr. 1081). Cancer Res 2009; 69:S565.
3. Di Leo A, Biganzoli L, Claudion W, Licitra S, Pestrin M, Larsimont D: Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime Eur J Cancer 2008; 44: 2791-2798.
4. Järvinen TA, Liu ET: HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003; 78: 299-311. (Pubitemid 36543210)
5. Isaacs RJ, Davies SL, Sandri MI, Redwood C, Wells NJ, Hickson ID: Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta 1998; 1400: 121-137. (Pubitemid 28475099)
6. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ: HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in nodepositive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116. (Pubitemid 34517647)
7. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490. (Pubitemid 46291811)
8. Nielsen KV, Ejlertsen B, Moller S, Jorgensen JT, Knoop A, Knudsen H, Mouridsen HT: The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 2008; 47: 725-734. (Pubitemid 351878451)
9. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L: Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 2009; 27: 3430-3436.
10. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2009; 101: 644-650.
11. Arriola E, Rodriguez-Pinilla SM, Lambros MBK, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS: Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat 2007; 106: 181-189. (Pubitemid 350045015)
12. Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K: Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol 2010; 136: 1029-1037.
13. Slamon D, Eiermann W, Robert N et al: BCIRG 006: 2nd interim analysis phase II randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel positive early (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study (abstract 1). Breast Cancer Res Treat 2005; 94:S5.
14. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J: Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006; 24: 2428-2436. (Pubitemid 46630618)
15. Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M: Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast 2008; 17: 506-511.
16. Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ: Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 2010; 120: 481-489.
17. Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK: Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 2005; 92: 69-75. (Pubitemid 40875080)
18. Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D: Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther 2004; 3: 1207-1214. (Pubitemid 39440165)
19. Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M: Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast Cancer Res Treat 2009; 113: 454-466.
20. Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC: ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010; 16: 2391-2401.
21. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R: Relationship between topoisomerase 2A RNA expression and recurrence after adjuvant chemotherapy for breast cancer. Clin Cancer Res 2009; 15: 7693-7700.
22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47: 207-214. (Pubitemid 11167383)
23. Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G, Otto HF: Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994; 54: 552-558. (Pubitemid 24351114)
24. Nocito A, Kononen J, Kallioniemi OP, Sauter G: Tissue microarrays (TMAs) for highthroughput molecular pathology research. Int J Cancer 2001; 94: 1-5. (Pubitemid 32801745)
25. Park K, Kim J, Lim S, Han S: Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003; 395: 631-634. (Pubitemid 36287375)
26. Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF: Outcome of patients with earlystage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 2009; 27: 3881-3886.
27. Bhargava R, Lal P, Chen B: HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol 2005; 123: 889-895. (Pubitemid 40740688)
28. Gómez HL, Pinto JA, Olivera M, Vidaurre T, Doimi FD, Vigil CE, Velarde RG, Abugattas JE, Alarcón E, Vallejos CS: Topoisomerase II-alpha as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. Breast 2011; 20: 39-45.
29. Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy JY, Rouas G, Sotiriou C, Renard N, Richard V, Piccart MJ, Di Leo A: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 2004; 24: 201-209.
30. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, Michel J, Focan CH, Ries F, Gobert PH, Closon-Dejardin MT, Dolci S, Rouas G, Paesmans M, Lobelle JP, Isola J, Piccart MJ: HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12: 1081-1089. (Pubitemid 32834488)
31. Gunnarsdóttir KA, Jensen MB, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B: CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Res Treat 2010; 123: 163-169.
32. Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ: Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 2006; 95: 1334-1341. (Pubitemid 44760082)
33. Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S: Topo2-protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. Br J Cancer 2010; 103: 1794-1800.
34. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ: Alteration of topoisomerase iialpha gene in human breast cancer: association with responsiveness to anthracyclinebased chemotherapy. J Clin Oncol 2011; 29: 859-867.
35. Mueller RE, Parkes RK, Andrulis I, O'Malley FP: Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004; 39: 288-297. (Pubitemid 38326310)
36. Callagy G, Pharoah P, Chin SF, Sangan T, Daigo Y, Jackson L, Caldas C: Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. J Pathol 2005; 205: 388-396. (Pubitemid 40253928)
37. Järvinen TA, Kononen J, Pelto-Huikko M, Isola J: Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 1996; 148: 2073-2082. (Pubitemid 26170530)